Description
Nivolumab/relatlimab, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[3] It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.
Get Access to OPDUALAG (nivolumab and relatlimab-rmbw) injection In India
On request it available to patient and doctors. Medvitaz Pharma is equipped to facilitate the distribution of OPDUALAG (nivolumab and relatlimab-rmbw) injection (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “OPDUALAG (nivolumab and relatlimab-rmbw) injection” or the generic version “nivolumab and relatlimab-rmbw injection” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.